Almac Diagnostics Leverages TruSight® Tumour 170 to Advance Clinical Research

Press/Media: Other

Description

The recently launched TruSight Tumor 170 integrates DNA and RNA into one protocol to accelerate comprehensive analysis of cancer-related variants and maximize the data obtainable from precious specimens. Designed to support limited nucleic acid input (40ng of DNA and RNA) from formalin-fixed, paraffin-embedded (FFPE) samples, TruSight Tumor 170 facilitates efficient evaluation of biomarkers

Period31 Mar 2017

Media contributions

1

Media contributions

  • TitleAlmac Diagnostics Leverages TruSight® Tumour 170 to Advance Clinical Research
    Degree of recognitionInternational
    Media name/outletIllumina
    Media typePrint
    CountryUnited Kingdom
    Date31/03/2017
    DescriptionThe recently launched TruSight Tumor 170 integrates DNA and RNA into one protocol to accelerate comprehensive analysis of cancer-related variants and maximize the data obtainable from precious specimens. Designed to support limited nucleic acid input (40ng of DNA and RNA) from formalin-fixed, paraffin-embedded (FFPE) samples, TruSight Tumor 170 facilitates efficient evaluation of biomarkers
    URLhttps://www.illumina.com/company/news-center/feature-articles/trusight-tumor-170-beta-site-interview.html
    PersonsPaul Harkin